Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "COVID"

1142 News Found

Pfizer and BioNTech receive U.S. FDA EUA for Covid-19 booster
Drug Approval | September 23, 2021

Pfizer and BioNTech receive U.S. FDA EUA for Covid-19 booster

Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups


DCGI approves Ampio Pharma’s Phase II trials to tackle Covid-19 induced respiratory distress
Biotech | September 22, 2021

DCGI approves Ampio Pharma’s Phase II trials to tackle Covid-19 induced respiratory distress

Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs


Pfizer and BioNTech’s Covid-19 vaccine safe for children aged 5 to 11: study
Biotech | September 21, 2021

Pfizer and BioNTech’s Covid-19 vaccine safe for children aged 5 to 11: study

In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year


India to resume export of Covid-19 vaccines from October
Policy | September 20, 2021

India to resume export of Covid-19 vaccines from October

The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month


India extends concession on life-saving Covid-19 drugs till December 2021
News | September 18, 2021

India extends concession on life-saving Covid-19 drugs till December 2021

The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines


LifeCell receives DCGI approval for Mesocel clinical trial to treat Covid-19
Biotech | September 17, 2021

LifeCell receives DCGI approval for Mesocel clinical trial to treat Covid-19

The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19


Novavax to participate in Oxford university’s study on combining Covid-19 vaccines
Biotech | September 17, 2021

Novavax to participate in Oxford university’s study on combining Covid-19 vaccines

Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age


Canada approves Moderna’s Covid-19 vaccine
Drug Approval | September 17, 2021

Canada approves Moderna’s Covid-19 vaccine

In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose


Unum designs vaccine verification tool to track Covid-19 vaccination status
Digitisation | September 17, 2021

Unum designs vaccine verification tool to track Covid-19 vaccination status

It will also manage test result documentation for employees who are not vaccinated, sending weekly reminders and employer notification


Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment
News | September 15, 2021

Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment

These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients